Careers

Diversity

With 17 offices, from New York to Los Angeles and Seattle to Orlando, we live and work in communities all over the U.S., collaborating across locations, disciplines and even borders. Our experienced, highly ranked lawyers serve businesses wherever they are and wherever they want to go.

Offices

About Us

Pages

Professionals

Thought leadership: blogs, podcasts, videos, publications, events and news

Insights

Services

Pro Bono

Am Law 100 firm with practices in Business, Digital Assets and Data Management, Intellectual Property, Labor & Employment, Litigation and Tax.

Home | BakerHostetler

FTC Issues Final Rule Banning Non-Competes

2024 BHIPP - BakerHostetler IP Perspective

Are Your Granted Patents in Danger of a Post-Grant Double Patenting Challenge?

IP Intelligence Report

World IP Day – Celebrating Innovation and Creativity to Build Our Common Future

Employment Law Spotlight

The Birth of Another Form of Paid Leave: Prenatal Leave for New York-Based Employees

In August 2022, Partner Lee Rosebush updated “Due Diligence in Drug Compounding M&amp;A Deals,” published as a LexisNexis Practical Guidance article and originally written with Associate Marc Wagner. The article addresses regulatory risk reduction in mergers and acquisitions between compounding pharmacies and focuses particular attention on Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FDCA).

<a href="/wp-content/uploads/2023/07/Due-Diligence-in-Drug-Compounding-MA-Deals.pdf" target="_blank" rel="noopener"><strong>Read the update.</strong></a>

<a href="/webfiles/Due Diligence in Drug Compounding M&amp;A Deals.pdf" target="_blank" rel="noopener"><strong>Read the original article.</strong></a>

core/freeform

Washington, D.C.

Partner

Lee H. Rosebush

Industries

Life Sciences

Lee Rosebush Updates Article Written With Marc Wagner About Drug Compounding M&A Deals

Related Services

Featured Insights